Use of PRP in Open Surgery for Type A Aortic Dissection
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorBeijing Anzhen Hospital
About this trial
The goal of this clinical trial is to determine if autologous platelet rich plasma (PRP) can reduce the need for blood transfusions in patients undergoing open surgery for Type A aortic dissection. It will also evaluate the potential organ-protective effects of autologous PRP. The main questions it aims to answer are:
1. Does PRP reduce the amount of allogeneic red blood cell transfusions for participants? 2. Does PRP administration provide protective effects on organs (heart, liver, lungs, kidneys, brain) in participants?
Researchers will compare the administration of autologous PRP with no PRP infusion to assess whether PRP can reduce blood transfusions and provide organ-protective effects in patients undergoing open surgery for Type A aortic dissection.
Participants will:
1. Receive autologous PRP infusion during surgery 2. Undergo multiple checkups and tests before and after surgery 3. Be recorded for allogeneic red blood cell usage within 24 hours perioperatively and all allogeneic blood products usage during the entire hospitalization 4. Be assessed for organ function (heart, liver, lungs, kidneys, brain) and symptom-related outcomes through clinical evaluations
Eligibility criteria
Qualifiers
Undergoing open surgery for type A aortic dissection (TAAD);
Body weight between 60-100 kg; hemoglobin (Hb) > 120 g/L; platelet count (PLT) ≥ 120 × 10⁹/L;
Able to understand the purpose of the study, voluntarily participate, and sign the informed consent form.
Disqualifiers
Requires mechanical ventilation before surgery;
Age under 18 or over 70 years;
Use of anticoagulant or antiplatelet drugs within 7 days before surgery;
Cardiogenic shock, cardiac arrest, severe hypotension (requiring two or more vasopressors), or mechanical circulatory support within 24 hours before surgery;
Trial design
Treatments tested in this trial
- Autologous Platelet Rich Plasma
- Standard Blood Management
Treatment groups
250 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Beijing Anzhen Hospital
Lead sponsor
Guangdong Provincial People's Hospital
Collaborator
Xiangya Hospital of Central South University
Collaborator
Guangzhou First People's Hospital
Collaborator
Source ClinicalTrials.gov